まとめグローバル遅発性ジスキネジア（TD）治療薬市場は、2015年から2019年までのCAGR xx％でxxx百万米ドルと評価されました。 その後、2020年にはXXX百万米ドルに達し、2020年から2025年までのCAGRはxx％になります。
世界の遅発性ジスキネジア（TD）治療薬市場では、このレポートは特に北アメリカ、南アメリカ、ヨーロッパとアジア太平洋、および中東とアフリカに焦点を当てています。 このレポートは、アプリケーション、タイプ、地域、および製造業者に基づいて市場を分類します。
メーカー別の市場細分化では、レポートは次の企業をカバーしています-
GlaxoSmithKline plc.
Bayer AG
Biogen
Teva Pharmaceutical Industries
Neurocrine Biosciences, Inc.
Pfizer Inc.
AstraZeneca
Novartis AG
Sanofi
地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋（中国、日本、韓国、インド、東南アジア）
南アメリカ（ブラジル、アルゼンチン、コロンビアなど）
中東およびアフリカ（サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）
タイプによる市場細分化：
Valbenazine
Deutetrabenazine
アプリケーションによる市場細分化：
病院
診療所
他人
この調査は、次の重要な質問に対する回答を提供します。
• 2020年から2025年の予測期間における遅発性ジスキネジア（TD）治療薬市場の推定成長率と市場シェアおよび規模はどのくらいですか？
• 予測期間2020年から2025年の遅発性ジスキネジア（TD）治療薬市場の原動力は何ですか？
• 著名なマーケットプレーヤーは誰ですか？彼らは他の競合他社に対してどのように競争力を獲得しましたか？
• 世界中の遅発性ジスキネジア（TD）治療薬の業界の進歩に影響を与える市場動向は何ですか？
• 業界の進歩を制限する主な課題と脅威は何ですか？
• 市場は著名な市場プレーヤーにとってどのような機会を持っていますか？
このレポートに関する特別な要件がある場合は、お知らせください。カスタムレポートを提供できます。
注–より正確な市場予測を提供するために、COVID-19の影響を考慮して、すべてのレポートが配信前に更新されます。
Table of Contents
1 Tardive Dyskinesia (TD) Treatment Drugs Market Overview
1.1 Product Overview and Scope of Tardive Dyskinesia (TD) Treatment Drugs
1.2 Classification of Tardive Dyskinesia (TD) Treatment Drugs by Types
1.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Comparison by Types (2020-2025)
1.2.2 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Types in 2018
1.2.3 Valbenazine
1.2.4 Deutetrabenazine
1.3 Global Tardive Dyskinesia (TD) Treatment Drugs Market by Application
1.3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Tardive Dyskinesia (TD) Treatment Drugs Market by Regions
1.4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Tardive Dyskinesia (TD) Treatment Drugs Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Tardive Dyskinesia (TD) Treatment Drugs Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Tardive Dyskinesia (TD) Treatment Drugs Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Tardive Dyskinesia (TD) Treatment Drugs Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Tardive Dyskinesia (TD) Treatment Drugs Status and Prospect (2015-2025)
1.5 Global Market Size of Tardive Dyskinesia (TD) Treatment Drugs (2015-2025)
2 Company Profiles
2.1 GlaxoSmithKline plc.
2.1.1 Business Overview
2.1.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.2 Bayer AG
2.2.1 Business Overview
2.2.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.3 Biogen
2.3.1 Business Overview
2.3.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Biogen Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.5 Neurocrine Biosciences, Inc.
2.5.1 Business Overview
2.5.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.6 Pfizer Inc.
2.6.1 Business Overview
2.6.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.7 AstraZeneca
2.7.1 Business Overview
2.7.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.8 Novartis AG
2.8.1 Business Overview
2.8.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
2.9 Sanofi
2.9.1 Business Overview
2.9.2 Tardive Dyskinesia (TD) Treatment Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sanofi Tardive Dyskinesia (TD) Treatment Drugs Revenue, Gross Margin and Market Share (2017-2019)
3 Global Tardive Dyskinesia (TD) Treatment Drugs Market Competition, by Players
3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Tardive Dyskinesia (TD) Treatment Drugs Players Market Share
3.2.2 Top 10 Tardive Dyskinesia (TD) Treatment Drugs Players Market Share
3.3 Market Competition Trend
4 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Regions
4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Market Share by Regions
4.2 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
4.3 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
4.5 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
5 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries
5.1 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries (2015-2019)
5.2 USA Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
5.3 Canada Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
5.4 Mexico Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
6 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries
6.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries (2015-2019)
6.2 Germany Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
6.3 UK Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
6.4 France Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
6.5 Russia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
6.6 Italy Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries
7.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries (2015-2019)
7.2 China Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
7.3 Japan Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
7.4 Korea Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
7.5 India Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
8 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries
8.1 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries (2015-2019)
8.2 Brazil Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
8.3 Argentina Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
8.4 Colombia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Tardive Dyskinesia (TD) Treatment Drugs by Countries
9.1 Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue by Countries (2015-2019)
9.2 Saudi Arabia Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
9.3 UAE Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
9.4 Egypt Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
9.5 Nigeria Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
9.6 South Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue and Growth Rate (2015-2019)
10 Global Tardive Dyskinesia (TD) Treatment Drugs Market Segment by Type
10.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue and Market Share by Type (2015-2019)
10.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Type (2020-2025)
10.3 Valbenazine Revenue Growth Rate (2015-2025)
10.4 Deutetrabenazine Revenue Growth Rate (2015-2025)
11 Global Tardive Dyskinesia (TD) Treatment Drugs Market Segment by Application
11.1 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Application (2015-2019)
11.2 Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Application (2020-2025)
11.3 Hospitals Revenue Growth (2015-2019)
11.4 Clinic Revenue Growth (2015-2019)
11.5 Others Revenue Growth (2015-2019)
12 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast (2020-2025)
12.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast (2020-2025)
12.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Forecast by Regions (2020-2025)
12.3 North America Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Forecast (2020-2025)
12.4 Europe Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Forecast (2020-2025)
12.6 South America Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
